Introduction
The U.S. Census Bureau projects that the U.S. Hispanic/Latino (H/L) population will reach 119 million by 2060. 1 However, H/L individuals represent only 3% of patients characterized in The Cancer Genome Atlas (TCGA) and indigenous Americans represent less than 0.5%. 2 Because precision medicine is driven by data that primarily represent non-Hispanic white (NHW) patients, there is a significant potential health disparity for underrepresented groups. [3] [4] [5] [6] NSCLC is the leading cause of cancer death among H/L men and second only to breast cancer in H/L women. 3 In NHW individuals, half of NSCLC cases have been shown to possess at least one of several known driver mutations, including alterations in KRAS, EGFR, MNNG HOS Transforming gene (MET), erb-b2 receptor tyrosine kinase 2 gene (HER2), BRAF, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), AKT/serine threonine kinase 1 gene (AKT1), mitogen-activated protein kinase kinase 1 gene (MAP2K1), ALK receptor tyrosine kinase gene (ALK), and MEK. 7 African Americans demonstrate a similar frequency of these mutations. 8 The frequency of EGFR mutations has been extensively studied for some groups and determined to be approximately 30% for Asian, 15% for NHW, and 19% to 21% for African American populations. 5, 9 However, a recent study of 241 African Caribbean patients found EGFR mutations to be common (37%). 10 Studies in H/L individuals have indicated an elevated frequency of EGFR mutations relative to that in NHW individuals. 11, 12 Other common mutations in lung cancer among H/L individuals have not been sufficiently investigated. 4, 13 To address the lack of molecular data for H/L individuals, our group established the Latino Lung Cancer Registry. We describe here our initial characterization of 163 H/L patients with lung cancer.
Methods

Patients and Tissues
Supplementary Table 1 summarizes the demographics of the cohort overall and by site of collection. The most common histologic type in the cohort was adenocarcinoma (120 [74%]), followed by squamous cell carcinomas (27 [17%]). Known female patients (78) outnumbered known male patients (66), and never-smokers (45) represented 36% of those with known smoking status. We subjected the available samples to AIM analysis to define the relative contributions of European, African American, and indigenous American ancestries in the cohort and in each individual patient. Overall, the cohort was primarily European (67%), followed by indigenous American (21%) and then of African ancestry (12%). African ancestry was enriched in the Puerto Rican subcohort, and indigenous American ancestry was enriched in the group from Perú. Figure 1A presents the mutation frequency in the four most common drivers in lung adenocarcinoma in NHW and H/L patients. For H/L patients, within the adenocarcinoma histologic type, 37 (31%) had one or more EGFR variants and 17 (14%) had KRAS variants. This analysis also showed a trend toward reduced rates in serine/threonine kinase 11 gene (STK11) mutations (p ¼ 0.065). The mutation rate of tumor protein p53 gene (TP53) was indistinguishable (p ¼ 0.717) between H/L (49%) and NHW patients (46%). Supplementary Table 2 lists other genes that may be mutated at a different frequency in H/L patients compared with in NHW patients.
Results
Patient Characteristics
Prevalence of Somatic Mutations
The relationship between driver mutations and patient characteristics was also explored. Figure 1B presents the mutation rates of EGFR, KRAS, STK11, and TP53 in male and female patients in each group. Notably, the rate of EGFR mutations was nearly 50% in H/L female patients. Mutations in KRAS and STK11 were reduced in female H/L patients and to a lesser extent in male H/L patients. The rate of TP53 mutations was similar between male and female patients (see Supplementary Table 3 for p values). Figure 1C presents a comparison between ever-smokers and never-smokers among H/L and NHW patients. Mutation rates in KRAS and STK11 were much higher in smokers for both the H/L and NHW cohorts. In fact, no STK11 mutations were observed in the 45 H/L never-smokers. In NHW patients, EGFR mutations were four times more common in neversmokers than in smokers. In the H/L cohort, this effect was much smaller. Mutations in TP53 were not strongly associated with smoking in either cohort. Finally, mutations were examined as a function of smoking by sex. Although the numbers are too small for statistical significance (see Supplementary Table 5 ), Figure 1D reveals that EGFR mutations in male patients in the H/L cohort were reduced in smokers but there was no difference detected in female smokers versus in nonsmokers. In contrast, a similar analysis in NHW patients (Fig. 1E) shows a clear increase in EGFR mutations in both male and female nonsmokers.
In general, H/L individuals are characterized by a wide mixture of ancestries. Therefore, to explore the role that ancestry may play in mutation frequency in the H/L cohort, the Ward linkage method and Euclidean distance metric were used to separate the cohort into three ancestral clusters (Fig. 2A) . The mutation frequency of various genes was then compared between the three clusters. Figure 2B reveals that EGFR mutations were more common in the indigenous American cluster but appeared identical in the European and African clusters (see Supplementary Table 7 for p values). In contrast, TP53 mutations were much less common in the indigenous American cluster, whereas the frequency of TP53 mutations appeared identical in the European and African clusters. KRAS mutations were shown to be rare in the African cluster, and STK11 mutations were rare in both the African and indigenous American clusters relative to in the European cluster.
Discussion
In previous reports, EGFR exhibited a higher rate of mutation and KRAS was suggested to have a lower mutation rate in H/L patients than in NHW patients. 3, 4, 11, 14 The data presented here confirm these observations. Of the 120 H/L adenocarcinomas that we analyzed, 37 (31%) had EGFR mutations compared with 17% in our TCC NHW cohort, and 17 H/L patients (14%) had KRAS mutations. In a published NHW cohort, 11% of lung adenocarcinomas had EGFR mutations and 35% had KRAS mutations. 15 In addition, our data suggest that the increase in EGFR mutations within our H/L cohort is driven by females, with 48% having EGFR mutations (Fig. 1B) . Our data also suggest altered mutation rates for other genes commonly mutated in NSCLC. Among patients with adenocarcinoma, the frequencies of KRAS and STK11 mutations were reduced in H/L patients relative to those in NHW patients.
Smoking is the primary driver of mutations in lung cancer. The overall percentage of nonsmokers in the H/L cohort was 36%. In comparison, an NHW cohort showed 9% nonsmokers 15 and the TCGA lung adenocarcinoma cohort showed 7% nonsmokers. Nonetheless, H/L individuals appeared to have a pattern similar to that a The Moffitt cohort includes seven carcinoids; three non-small cell lung carcinomas, not otherwise specified; two large cell carcinomas; and one adenosquamous carcinoma. The Puerto Rico cohort contains three carcinomas, not otherwise specified, and one NSCLC, not otherwise specified. PR, Puerto Rico; NA, not available.
observed in NHW individuals for STK11 and KRAS in that mutations in both genes increase with smoking in both groups (Fig. 1C) . Unlike in NHWs, mutations in TP53 occurred with nearly equal frequency in both smoking groups in the H/L cohort and the inverse correlation between smoking and EGFR mutations was dampened in H/L patients. These results suggest that smoking status is not the primary factor explaining the high rate of EGFR mutations in H/L patients. The observation that KRAS and STK11 mutations are increased in H/L smokers addresses the objection that H/L ever-smokers are lighter smokers than NHW individuals are. There may be Table 3 for p values. (C) Mutation rate comparison between H/L (and NHW) ever-smokers and never-smokers. Although statistically insignificant, the trend suggests that EGFR mutations are seen more commonly in nonsmokers, whereas KRAS and seronine/threonine kinase 11 gene (STK11) mutations are more frequently seen in smokers. See Supplementary Table 4 for p values. (D) Mutation rate comparison between H/L male and female patients and ever-smokers and never-smokers. Although statistically insignificant, the trend suggests that EGFR mutations are seen more commonly in nonsmokers, whereas KRAS and STK11 mutations are more frequently mutated in smokers. See Supplementary Table 5 for p values. (E) Mutation rate comparison between NHW males and female patients and ever-smokers and never-smokers. See Supplementary Table 6 for p values. TP53, tumor protein p53 gene.
differences in how smoking influences the mutations observed in men versus in women ( Fig. 1D and E) . However, drawing this conclusion firmly will require a larger data set. Regardless of the cause, the significant differences in specific mutations, and in mutation burden, suggest that special consideration be given to H/Ls patients considered for immune therapeutic approaches. For example, future studies should carefully examine the expression of targetable immune components in H/L patients. Finally, the role that ancestry might play in this cohort was examined by clustering patients into ancestral groups on the basis of AIM analyses (Fig. 2A) .
Whereas the analysis results are statistically significant only for the TP53 mutations, the data (Fig. 2B) suggest that relative to European ancestry, indigenous American ancestry correlates with low rates of TP53 and STK11 mutations and high rates of EGFR mutations and African ancestry correlates to low rates of KRAS mutations. At this point, our data set is too small to make claims with respect other mutations that are even less common than these four.
There are a few notable study limitations worth addressing. One of the most significant was the lack of matched normal samples for each of the sequenced tumors. Likewise, we utilized various sources of tissue and various sequencing technologies. These issues should be considered when interpreting these data. Other limitations include incomplete clinical data for several samples in our cohort (which affected our ability to determine statistical significance) and lack of age, tumor stage, and outcome data. Future studies will be necessary to provide statistical power for additional comparisons. Nonetheless, this study is the first addressing the lack of comprehensive genomic data in H/L patients with lung cancer. The data suggest that EGFR mutations in H/L patients with lung adenocarcinoma are associated with their indigenous American ancestry. This observation may point to connection to a genetic component from Asian-Pacific migration because it is known that the EGFR mutation rate is high among Asian patients. 5 Future studies will need to expand this study to fully elucidate the role that ancestry is playing in the mutation driving lung cancer.
